You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

440 Results
Drug
Other Name(s): Trisenox®
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut),
bortezomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Oct 2025
Drug
Other Name(s): Columvi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Drug
Other Name(s): Tecvayli®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Drug
Other Name(s): Epkinly™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Drug
Other Name(s): Kimmtrak®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Drug
Other Name(s): Blincyto®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
daratumumab,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Oct 2025

Pages